Insider sale details
Dawn Christine Maroney, president of Alignment Healthcare, Inc. (NASDAQ:ALHC), executed a sale of 30,000 shares of common stock on February 17, 2026, collecting $618,990 in gross proceeds. The trades were carried out at prices ranging from $20.05 to $20.99, levels described as being close to the then-current share price of $20.59.
Remaining holdings and company size
Following the disposition, Maroney retains direct ownership of 997,015 shares in Alignment Healthcare. The company carries a market capitalization of $4.11 billion.
Timing and reporting
The sale was conducted under a pre-arranged Rule 10b5-1 trading plan that Maroney adopted on May 22, 2025. Alignment Healthcare is scheduled to report quarterly results on February 26, described in the available data as just 8 days away from the transaction date.
Profitability and analyst expectations
Alignment Healthcare has not been profitable over the last twelve months. However, InvestingPro analysis referenced alongside the transaction indicates that analysts expect the company to achieve profitability this year.
Share performance and valuation context
InvestingPro data included with the report show that ALHC has returned 49.2% over the past year and 34.66% over the last six months. The stock is described as trading slightly above its Fair Value in that dataset.
Membership outlook and recent guidance
Management has set expectations for year-end 2026 health plan membership in a range between 290,000 and 296,000 members. That projection represents roughly 24% to 27% growth versus the company’s projected 2025 membership. For context, Alignment Healthcare reported approximately 275,300 members as of January 1, representing a 31% year-over-year increase.
Analyst moves and market reception
Several broker-dealer research teams have updated their views in light of the company’s results and guidance. KeyBanc raised its price target for Alignment Healthcare to $28 while maintaining an Overweight rating, highlighting expected membership expansion and EBITDA guidance in line with consensus. Piper Sandler increased its target to $30, citing strong sales and retention during the Annual Enrollment Period and anticipated higher membership in 2026. JPMorgan upgraded its rating to Overweight from Neutral and lifted its price target to $20, citing the company’s strong 2025 performance and positioning in the Medicare Advantage market. Collectively, these revisions are presented as reflecting a positive analyst outlook on Alignment Healthcare’s growth trajectory.
Resources for investors
The reporting notes that investors tracking insider activity and company fundamentals can access additional insights via InvestingPro, which offers 10 additional ProTips about ALHC and a comprehensive Pro Research Report designed to translate Wall Street data into actionable information.
Note on limitations - The piece reports the transaction and analyst commentary as provided in the available data. It does not add or infer information beyond the stated figures, ownership levels, membership projections, analyst actions, or the timing of the earnings release.